Drug Trial News

RSS

Immunotherapy combination increases overall survival in people with kidney cancer, study shows

Treating people with advanced metastatic kidney cancer using a combination of the immunotherapy drugs nivolumab (Opdivo) and ipilimumab (Yervoy) significantly increased overall survival versus treatment with sunitinib (Sutent) alone, according to new findings from researchers at Memorial Sloan Kettering Cancer Center that were reported today in the New England Journal of Medicine.

22 Mar 2018

ACTA trial in AIDS patients with cryptococcal meningitis validates new therapeutic regimens

The results of the ACTA trial were presented at the 9th IAS Conference on HIV Science held in Paris from 23 to 26 July 2017. Professor Thomas Harrison and his colleagues at St George's University of London, the Institut Pasteur in Paris, Paris Descartes University (Hôpital Necker-Enfants Malades), the ANRS site in Cameroon, and the MRC sites in Malawi, Tanzania, and Zambia show in this trial that new therapeutic regimens are of benefit in HIV-infected patients with cryptococcal meningitis.

15 Mar 2018

PAREXEL and CHA collaborate to improve early phase clinical development in Korea

PAREXEL International Corporation, the world’s leading innovator of biopharmaceutical services, today announced an alliance with CHA Medical Group to enhance early phase clinical development in Korea.

From Parexel 14 Mar 2018

Blood-thinning drug mitigates risk of complications, death after non-cardiac surgery

Researchers in Hamilton have discovered that a blood-thinning drug, dabigatran, significantly reduces the risk of death, heart attack, stroke, and other heart or blood-vessel complications in patients who have a heart injury following major, non-cardiac surgery.

12 Mar 2018

Inhaled therapy for heart failure fails to meet either primary or secondary endpoints

Four weeks of treatment with a novel inhaled medication failed to improve exercise capacity, daily activity levels, severity of symptoms or quality of life in patients with a type of heart failure for which no effective treatment options currently exist, according to research presented at the American College of Cardiology's 67th Annual Scientific Session.

12 Mar 2018

PCSK9 inhibitor reduces cardiovascular events in ACS patients with high cholesterol

Among patients with persistently high cholesterol despite high-intensity statin therapy, the proprotein convertase subtilisin-kexin 9 (PCSK9) inhibitor alirocumab reduced rates of major adverse cardiovascular events by 15 percent compared with placebo, in a study presented at the American College of Cardiology's 67th Annual Scientific Session.

12 Mar 2018

Gastrointestinal hormone offers possible new treatment for NAFLD and NASH patients

Through a randomized, double-blind, placebo-controlled phase II clinical trial, researchers at University of California San Diego School of Medicine report that small doses of NGM282, a non-tumorigenic variant of an endocrine gastrointestinal hormone, can significantly and rapidly decrease liver fat content in patients with non-alcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH).

9 Mar 2018

One-month antibiotic regimen to prevent TB as safe, effective as nine-month therapy for HIV patients

A one-month antibiotic regimen to prevent active tuberculosis (TB) disease was at least as safe and effective as the standard nine-month therapy for people living with HIV, according to the results of a large international clinical trial.

6 Mar 2018

New treatment shows promise to fight against serious inflammatory disease

Still's disease is a serious orphan disease manifested by high fevers, skin and joint involvement, including paralysis, as well as damage to other organs such as the liver or spleen. It is caused by a deregulation of the immune system triggering an acute inflammatory response.

27 Feb 2018

U.S. clinical sites evaluating antibody-based therapies to prevent two common bacterial infections

The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, is supporting U.S. clinical sites participating in two ongoing international Phase 2 clinical trials evaluating investigational antibody-based therapies aimed at preventing potentially antibiotic-resistant infections.

23 Feb 2018

New data from VOYAGE 2 trial shows promising results for Janssen’s guselkumab treatment

The Janssen Pharmaceutical Companies of Johnson & Johnson announced today new data that showed a vast majority of patients with moderate to severe plaque psoriasis receiving TREMFYA (guselkumab), who achieved at least a 90 percent improvement in the Psoriasis Area and Severity Index (PASI 90) at week 28, maintained a PASI 90 response with continuous treatment through week 72.

From J&J Innovative Medicine 22 Feb 2018

First African child vaccinated with new typhoid conjugate vaccine

Today the University of Maryland School of Medicine's Center for Vaccine Development is proud to be part of vaccine history in Africa.

22 Feb 2018

People with major depressive disorder have reduced arginine levels, study shows

People suffering from major depressive disorder, MDD, have reduced arginine levels, a new study from the University of Eastern Finland shows. Arginine is an amino acid which the body uses to produce, e.g., nitric oxide.

21 Feb 2018

Clinical trial shows safety of promising TSRI stroke drug

A preliminary Phase 2 clinical trial has demonstrated that patients with acute ischemic stroke, the most common type of stroke, can safely tolerate high doses of 3K3A-APC, a promising anti-stroke drug invented at The Scripps Research Institute.

20 Feb 2018

Gout medication may help improve heart function in adult patients

Researchers at the University of Cincinnati College of Medicine have shown that probenecid, a drug long used to treat gout, may be able to improve heart function in adult patients who experience heart failure.

20 Feb 2018

Clinical trial studying type 1 diabetes reaches full enrollment

A clinical trial studying type 1 diabetes has reached full enrollment. The Sanford Project: T-Rex Study, a Phase 2 clinical trial conducted collaboratively by Sanford Health and Caladrius Biosciences, Inc., has completed enrollment of 110 children with type 1 diabetes. The study started with two sites at Sanford Health in Sioux Falls, South Dakota, and Fargo, North Dakota, and expanded to 13 additional sites across the United States.

19 Feb 2018

Psoriasis drug also effective at reducing aortic inflammation

Ustekinumab, sold under the name Stelara, is approved by the U.S. Food and Drug Administration to treat psoriasis, psoriatic arthritis, and Crohn's Disease. Researchers wanted to know if the benefits of the drug go beyond clearing the skin.

18 Feb 2018

New medication improves motor function in children with later-onset spinal muscular atrophy

Children with later-onset spinal muscular atrophy (SMA) were more likely to show gains in motor function when treated with a new medication compared to children receiving a sham procedure, according to a study published today in the New England Journal of Medicine.

15 Feb 2018

Study shows safety, efficacy of intravenous bevacizumab treatment for HHT related bleeding

Intravenous bevacizumab should be considered as a first-line therapy for the treatment of refractory bleeding in patients with severe hereditary hemorrhagic telangiectasia, reports Mayo Clinic Proceedings

29 Jan 2018

Researchers test new anti-malaria medication

An international research team has conducted successful phase II clinical tests of a new anti-malaria medication. The treatment led to a cure in 83 cases.

19 Jan 2018

Drug Trial News

Immunotherapy combination increases overall survival in people with kidney cancer, study shows

ACTA trial in AIDS patients with cryptococcal meningitis validates new therapeutic regimens

PAREXEL and CHA collaborate to improve early phase clinical development in Korea

Blood-thinning drug mitigates risk of complications, death after non-cardiac surgery

Inhaled therapy for heart failure fails to meet either primary or secondary endpoints

PCSK9 inhibitor reduces cardiovascular events in ACS patients with high cholesterol

Gastrointestinal hormone offers possible new treatment for NAFLD and NASH patients

One-month antibiotic regimen to prevent TB as safe, effective as nine-month therapy for HIV patients

New treatment shows promise to fight against serious inflammatory disease

U.S. clinical sites evaluating antibody-based therapies to prevent two common bacterial infections

New data from VOYAGE 2 trial shows promising results for Janssen’s guselkumab treatment

First African child vaccinated with new typhoid conjugate vaccine

People with major depressive disorder have reduced arginine levels, study shows

Clinical trial shows safety of promising TSRI stroke drug

Gout medication may help improve heart function in adult patients

Clinical trial studying type 1 diabetes reaches full enrollment

Psoriasis drug also effective at reducing aortic inflammation

New medication improves motor function in children with later-onset spinal muscular atrophy

Study shows safety, efficacy of intravenous bevacizumab treatment for HHT related bleeding

Researchers test new anti-malaria medication

Unlocking live single-cell functional insights

Fluidics in Modern Healthcare & Medical Device Innovation

How microRNA is transforming science: From discovery to diagnostics

Latest News